Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07002216 · ClinicalTrials.gov registry record · Phase 2

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

A Phase 2 study of Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT07002216 is a Phase 2 study of Hodgkin Lymphoma and Advanced Hodgkin Lymphoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 48 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07002216, a Phase 2 study of Hodgkin Lymphoma and Advanced Hodgkin Lymphoma, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.

Conditions Studied

Hodgkin Lymphoma Advanced Hodgkin Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Etoposide
  • DRUG Brentuximab Vedotin
  • DRUG Dacarbazine

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-07-15
Est. Completion 2030-07-15
Phase Phase 2

Sponsor

University of Miami

721 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07002216

The ClinicalTrials.gov registry entry for NCT07002216 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (71% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT07002216 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07002216 about?

NCT07002216 is a clinical study titled "BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma". The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinica...

What is the current status of trial NCT07002216?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2025-07-15. Estimated completion is 2030-07-15.

What conditions does trial NCT07002216 study?

This clinical trial studies the following conditions: Hodgkin Lymphoma, Advanced Hodgkin Lymphoma.

What interventions are being tested in trial NCT07002216?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Etoposide (DRUG), Brentuximab Vedotin (DRUG), Dacarbazine (DRUG).

Who is sponsoring clinical trial NCT07002216?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07002216 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hodgkin Lymphoma

All registered trials for this condition

Advanced Hodgkin Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.